SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA issues Establishment Inspection Report for SMS Pharma’s Bachupally facility

22 Jan 2018 Evaluate

SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its facility - Unit-II, located at Plot No.24 & 24B and 36 & 37, S.V. Co-operative Industrial Estate, Bachupally, Ranga Reddy District, Hyderabad. This facility was inspected by USFDA in November 2017 and there were no ‘Form 483’ observations during the inspection.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. They are the single largest producer of anti-ulcer products.


SMS Pharmaceuticals Share Price

414.90 -5.70 (-1.36%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×